Randall Stoesz
Carmel, INNPI 1174503668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $736 and has fallen 75.6% since, to $180 in 2025.
Across 169 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$578
- Supernus Pharmaceuticals, Inc.$395
- Ironshore Pharmaceuticals Inc.$275
- Pfizer$248
- Corium, LLC$239
- Adlon Therapeutics L.p.$237
- plus $930 from 12 others
What the payments were for
- Food & beverage$2,902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 19 | $578 |
| Supernus Pharmaceuticals, Inc. | 47 | $395 |
| Ironshore Pharmaceuticals Inc. | 17 | $275 |
| Pfizer | 17 | $248 |
| Corium, LLC | 15 | $239 |
| Adlon Therapeutics L.p. | 13 | $237 |
| Merck | 9 | $234 |
| Tris Pharma Inc | 8 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $165 |
| Sanofi-aventis U.S. LLC | 3 | $76 |
| Arbor Pharmaceuticals, Inc. | 2 | $56 |
| Shire North American Group Inc | 3 | $45 |
| Sobi, Inc | 2 | $38 |
| Biogen | 1 | $29 |
| Neurelis, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quillivant$125
- Dyanavel XR$125
- Quillichew ER$125
- BEYFORTUS$120
- GARDASIL$117
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.